In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies

Since the first approval of monoclonal antibodies by the United States Food and Drug Administration (FDA) in 1986, therapeutic antibodies have become one of the predominant classes of drugs in oncology and immunology. Despite their natural function in contributing to antiviral immunity, antibodies a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Silvere Pagant, Rachel A. Liberatore
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	monoclonal antibodies plasmid DNA electroporation antiviral neutralizing antibody infectious disease Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/6f6f391b209048c09e5cae17cdd445d3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f6f391b209048c09e5cae17cdd445d3
record_format	dspace
spelling	oai:doaj.org-article:6f6f391b209048c09e5cae17cdd445d32021-11-25T18:41:25ZIn Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies10.3390/pharmaceutics131118821999-4923https://doaj.org/article/6f6f391b209048c09e5cae17cdd445d32021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1882https://doaj.org/toc/1999-4923Since the first approval of monoclonal antibodies by the United States Food and Drug Administration (FDA) in 1986, therapeutic antibodies have become one of the predominant classes of drugs in oncology and immunology. Despite their natural function in contributing to antiviral immunity, antibodies as drugs have only more recently been thought of as tools for combating infectious diseases. Passive immunization, or the delivery of the products of an immune response, offers near-immediate protection, unlike the active immune processes triggered by traditional vaccines, which rely on the time it takes for the host’s immune system to develop an effective defense. This rapid onset of protection is particularly well suited to containing outbreaks of emerging viral diseases. Despite these positive attributes, the high cost associated with antibody manufacture and the need for a cold chain for storage and transport limit their deployment on a global scale, especially in areas with limited resources. The in vivo transfer of nucleic acid-based technologies encoding optimized therapeutic antibodies transform the body into a bioreactor for rapid and sustained production of biologics and hold great promise for circumventing the obstacles faced by the traditional delivery of antibodies. In this review, we provide an overview of the different antibody delivery strategies that are currently being developed, with particular emphasis on in vivo transfection of naked plasmid DNA facilitated by electroporation.Silvere PagantRachel A. LiberatoreMDPI AGarticlemonoclonal antibodiesplasmid DNAelectroporationantiviralneutralizing antibodyinfectious diseasePharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1882, p 1882 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	monoclonal antibodies plasmid DNA electroporation antiviral neutralizing antibody infectious disease Pharmacy and materia medica RS1-441
spellingShingle	monoclonal antibodies plasmid DNA electroporation antiviral neutralizing antibody infectious disease Pharmacy and materia medica RS1-441 Silvere Pagant Rachel A. Liberatore In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
description	Since the first approval of monoclonal antibodies by the United States Food and Drug Administration (FDA) in 1986, therapeutic antibodies have become one of the predominant classes of drugs in oncology and immunology. Despite their natural function in contributing to antiviral immunity, antibodies as drugs have only more recently been thought of as tools for combating infectious diseases. Passive immunization, or the delivery of the products of an immune response, offers near-immediate protection, unlike the active immune processes triggered by traditional vaccines, which rely on the time it takes for the host’s immune system to develop an effective defense. This rapid onset of protection is particularly well suited to containing outbreaks of emerging viral diseases. Despite these positive attributes, the high cost associated with antibody manufacture and the need for a cold chain for storage and transport limit their deployment on a global scale, especially in areas with limited resources. The in vivo transfer of nucleic acid-based technologies encoding optimized therapeutic antibodies transform the body into a bioreactor for rapid and sustained production of biologics and hold great promise for circumventing the obstacles faced by the traditional delivery of antibodies. In this review, we provide an overview of the different antibody delivery strategies that are currently being developed, with particular emphasis on in vivo transfection of naked plasmid DNA facilitated by electroporation.
format	article
author	Silvere Pagant Rachel A. Liberatore
author_facet	Silvere Pagant Rachel A. Liberatore
author_sort	Silvere Pagant
title	In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
title_short	In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
title_full	In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
title_fullStr	In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
title_full_unstemmed	In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
title_sort	in vivo electroporation of plasmid dna: a promising strategy for rapid, inexpensive, and flexible delivery of anti-viral monoclonal antibodies
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6f6f391b209048c09e5cae17cdd445d3
work_keys_str_mv	AT silverepagant invivoelectroporationofplasmiddnaapromisingstrategyforrapidinexpensiveandflexibledeliveryofantiviralmonoclonalantibodies AT rachelaliberatore invivoelectroporationofplasmiddnaapromisingstrategyforrapidinexpensiveandflexibledeliveryofantiviralmonoclonalantibodies
_version_	1718410778676035584

In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies

Ejemplares similares